在以人环素为基础的化疗中,阿托瓦斯和左心室功能
Vencel Juhasz1, Zsofia D Drobni2, Thiago Quinaglia3
1Cardiovascular Imaging Research Center, Division of Cardiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts; Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
概括
在接受 antracyclines 治疗的淋巴瘤患者中,阿托瓦斯塔丁没有防止左心房应变的下降. 在这项研究中,阿托瓦斯塔丁与安慰剂组之间的左心房功能没有显著差异.
科学领域:
- 心脏病学
- 癌症学
- 药理学
背景情况:
- 左心房 (LA) 的结构和功能异常与心脏病的不良结果有关.
- 人环素对LA结构和功能的影响尚不完全理解.
- 已知阿托瓦斯塔丁对左心室喷射分数的保护作用,但其对LA的影响尚不清楚.
研究的目的:
- 调查阿托瓦斯塔丁是否减轻了因人环素引起的左心室结构和功能损伤.
- 评估阿托瓦斯塔丁对接受环素化疗的患者的LA菌株和体积测量的影响.
主要方法:
- 在STOP- CA随机临床试验中,纳入了用环素治疗的淋巴瘤患者.
- 参与者被随机分配给接受安慰剂或阿托瓦斯塔丁治疗12个月.
- 通过心血管磁共振 (CMR) 来测量LA体积和功能,包括全球纵向应变 (GLS),在基线和12个月使用特征追踪进行评估.
主要成果:
- 在阿托瓦斯和安慰剂组之间,没有观察到≥1SD或≥20%的LA GLS相对下降的参与者比例的显著差异.
- 在安慰剂组从基线到随访期间,LA GLS的降低.
- 在50岁以上的参与者中,无论阿托瓦斯塔丁治疗如何,阿特瓦斯塔丁治疗的LA GLS相对下降更大.
结论:
- 在接受以环素为基础的化疗治疗的淋巴瘤患者中,阿托瓦斯没有减轻CMR衍生的LA GLS的下降.
- 这项研究表明,阿托瓦斯塔丁不能防止与人环相关的左心脏功能受损.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
673
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
673
01:25Aortic Regurgitation III: Medical Management
42
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
42
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
45
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
45
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K